Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral Gástrica em uma mulher de 40 anos de idade. Abstract. DAL MASO, Rosina Conceição Graçaplena et al. Sex hormones in women on dialysis. Rev. Assoc. Med. Bras. [online]. , vol, n.4, pp . 22 out. Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral. Gástrica em uma mulher de.

Author: Shakazahn Yorr
Country: Slovenia
Language: English (Spanish)
Genre: Sex
Published (Last): 25 June 2005
Pages: 72
PDF File Size: 19.22 Mb
ePub File Size: 16.72 Mb
ISBN: 631-7-61926-227-7
Downloads: 29299
Price: Free* [*Free Regsitration Required]
Uploader: Nikogore

Thus, anticipating an ischaemic insult for example, kidney transplantation or renal arteries eritdopoetina during abdominal surgeryrecombinant EPO can be used as a kidney tissue protector. Update on erythropoiesis-stimulating agents.

Relevant Facts

J Exp Med ; Other laboratory findings showed normal total bilirubin 0. Regarding the mechanism of action, it acts as the native EPO, stimulating its receptor.

Pharmacology of darbepoetin alfa.

However, there is the possibility of promoting activation of other genes, like VEGF, as described with HIF stabilizers, further studies being needed. Finally, these experimental treatments for anaemia in CKD are not free of risks. In haemodialysis patients the intravenous route is preferred, but the subcutaneous administration can substantially reduce dose requirements and is the preferred eritropostina route in pre-dialysis, transplant or peritoneal dialysis patients, for economic and practical reasons.


C-reactive protein was 1. Biochem Pharmacol ;82 Since then, several ESAs have appeared, characterized by lower administration frequency and better stabilization of haemoglobin concentration.

Regulação da produção da eritropoietina e perspectivas terapêuticas na anemia

Similar Items Eritropoetina humana recombinante na anemia de prematuridade: Nephrol Dial Transplant ;19 2: The first human clinical trial began in Services on Demand Journal. The myelogram revealed an overgrowth of erythroid cell.

Since its discovery, much has been achieved in the knowledge of the biology of this glycoprotein. The major complication of blocking IL-6 recombinnte seems to be an increased risk of infections 55so this therapy should be confined to the treatment of serious diseases. There were no esophageal varices.

Sign in to the Lens

In normoxic conditions, HIF subunits are rapidly degraded by proteasomes, after binding with von Hippel-Lindau tumour suppressor VHLwhich is the recognition substrate of the ubiquitin E3 ligase complex that mediates the ubiquitination of HIF. Targeting HIF-1 for cancer therapy.


Anaemia; erythropoietin; GATA-2 inhibitors; hepcidin; hypoxia-inducible factors; kidney disease. Erythropoiesis stimulating agents ESA: End stage renal disease; Dialysis; Sex hormones; Women; Recombinant human erythropoietin.

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.

The same parameters were evaluated for the group that did not rHuEPO in this, there was no statistically significant humans. In the central nervous system, EPO is involved in neuroprotection, neurogenesis and angiogenesis, playing an important function as a neurotropic and immunomodulatory factor Am J Hematol ;87 4: Furthermore, they are able to modulate other genes involved in erythropoiesis, in particular those related with iron utilization: How to cite this article.


Glycolytic enzymes induction demonstrates the role of HIF in the autonomous cellular adaptation to hypoxia, producing ATP by glycolysis, instead of oxidative phosphorylation. However, endoscopy is a method of diagnosis, monitoring and treatment in these patients, but surgical treatment should be considered for patients who do not respond to endoscopic therapy.

In monkeys, its administration resulted in effective iron mobilization, with increased serum levels Erythropoietin has an action that exceeds erythropoiesis and plays an important role in cell protection.

As for the biochemical aspects of iron and ferritin, examined in this study, there was no relevance in the two groups and no difference between them.

This patient required blood transfusion for acute blood loss. Currently, the pharmacological treatment for anaemia in CKD includes therapy with erythropoiesis stimulating agents ESA eritropoetna supplementation with iron.